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Background: Transcription activator-like effector nucleases (TALENs) have emerged as a tool for enabling targeted
gene editing and disruption in difficult systems, such as human pluripotent stem cells (hPSCs). The modular
architecture of TAL effectors theoretically enables targeting of any genomic locus and several cloning systems
for custom TALEN assembly have recently been established. However, there is a lack of versatile TALEN expression
systems applicable to hPSCs.
Results: Here, we extend an existing TALE assembly system by a dual set of expression vectors for efficient
application of TALEN technology in hPSCs. This is characterized by improved TALEN architecture as well as
antibiotic resistance and fluorescent reporter cassettes, thus enabling enrichment for transfected cells.
Improved functionality of the combined system was demonstrated by targeted disruption of the HPRT1 gene to
create isogenic disease models of Lesch-Nyhan-Syndrome. Using female hPSCs, homozygous disruption of HPRT1
occurred at efficiencies of up to 15%. Differentiating isogenic knock-out cells both into central nervous system
(CNS) as well as into sensory-like neurons recapitulated previously described phenotypes based on patient-specific
induced PSCs and extended these findings to non-CNS neurons, respectively.
Conclusion: The combined vector system allows for flexible and affordable generation of knock-out hPSCs lines,
thus enabling investigation of developmental processes as well as the generation of isogenic disease models without
the need for patient material.
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Gene targeting in human pluripotent stem cells (hPSCs) by
conventional approaches is a cumbersome and inefficient
process. The development of sequence-specific nucleases,
such as TALENs, can, however, significantly enhance the
efficiency of genome editing in hPSCs [1]. TALENs are
chimeric fusions between custom-designed transcription
activator-like effectors (TALE) of Xanthomonas plant pa-
thogens and the FokI nuclease [2-4]. Within the TALE
structure, individual repeat domains confer specific recog-
nition and binding to single nucleotides on DNA. Several
types of repeat domains differing solely in their so-called* Correspondence: boris.greber@mpi-muenster.mpg.de
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reproduction in any medium, provided the orrepeat variable di-residues (RVDs) have been found to be
selective binders of individual DNA bases, with differing
affinities [5]. Custom design of the modular TALE repeat
domain structure hence allows specific targeting and bin-
ding of TALEs to genomic regions of interest. Upon pres-
ence and adjacent binding of two TALENs, a DNA
double-strand break (DSB) will be induced by the fused
catalytic domain of FokI nuclease, which is then repaired
either by the error-prone mechanism of non-homologous
end joining (NHEJ) or via homology-directed repair [6].
Hence, in the absence of homologous template sequence,
small genetic lesions may be introduced into a predefined
locus by delivery of pairs of specifically designed TALEN
constructs into cells, such as hPSCs [1,7].
Several approaches have been used for the generation
of custom TALENs [7-11]. These are, however, not easy
to adopt for new researchers entering the field [12].td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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larly straightforward TALEN assembly system that is
based on GoldenGate cloning. It enables reliable TALEN
assembly within a few days and has been made available
through the Addgene repository. However, the associ-
ated expression vectors were not optimized for applica-
tions in mammalian cells. We have therefore developed
a new set of vectors compatible with this publicly avai-
lable TALEN assembly kit [13]. Our plasmids contain an
improved TALEN backbone architecture incorporating
findings by Miller et al. [6] as well as selection cassettes
to enrich for transfected cells. Here, we report the appli-
cation of the combined system to hPSCs by creating iso-
genic knock-out models for the X-linked HPRT1 locus at
high efficiencies. Mutations in this gene cause Lesch-
Nyhan-Syndrome (LNS), a disease with strong neuro-
logical symptoms [14,15]. Clonal knock-out lines showed
impaired differentiation into different neuronal lineages,
recapitulating aspects of the disease phenotype in vitro.
The combined TALEN assembly-and-expression system
simplifies the custom generation of hPSC knock-out cell
lines and will therefore be universally applicable for




hPSCs were cultivated on Matrigel® in either MEF-
conditioned or defined FTDA media [16,17]. HEK-293 T
cells were cultured on conventional tissue culture plastic in
DMEM supplemented with 10% fetal bovine serum, non-
essential amino acids, 2-mercaptoethanol, and Penicillin-
Streptomycin-L-Glutamine.
TALEN design and assembly
TALE repeat structures were designed using either the
ZiFit targeter http://zifit.partners.org/ZiFiT/) or the TAL
Effector Nucleotide Targeter 2.0 (https://tale-nt.cac.cornell.
edu/node/add/talen). TALENs were assembled as pub-
lished [13], by following the protocol associated with the
GoldenGate TALEN and TAL Effector Kit 1.0 (Addgene
#1000000016), except that TALE repeats were ultimately
cloned into vectors pTAL7A (for TALEN A) and pTAL7B
(for TALEN B) (Additional file 1: Figure S1).
Pretesting of TALENs and generation of HPRT1 knock-out
lines
TALENs A and B were transfected into HEK-293 T cells or
hPSCs at equimolar ratios using Fugene 6 (Roche). Starting
from 24 hours after selection, antibiotic selection was ap-
plied for 48 hours with puromycin at 0.5 μg/ml and blasti-
cidin at 5 μg/ml. After selection, cells were dissociated and
(i) lysed to purify genomic DNA, (ii) analyzed via flow cy-
tometry, or (iii) reseeded for selection of knock-out cellsusing 6-thioguanine (6-TG, Sigma, #A4862). Mutation fre-
quencies were determined with the CEL-1 assay (Surveyor
Nuclease S, Transgenomic, #706020) according to the
manufacturer’s protocol. 6-TG was applied for 4–8 days at
a concentration of 30 μM.
Neuronal differentiation
Differentiation of hPSCs into neurons was performed as
previously described [18,19]. Quantification of neurite
length and percentage of beta-III-tubulin-positive neu-
rons was performed using Arrayscan XTI HCA high-
content imaging instrumentation (Thermo).
Availability of supporting data
The data sets supporting the results of this article are avai-
lable in the European Nucleotide Archive, IDs HG530137
and HG530138, http://www.ebi.ac.uk/ena/, as well as in
the Addgene plasmid repository, IDs 48705 and 48706,
http://www.addgene.org/.
Results
In order to create a vector system compatible with the
GoldenGate transcription-activator like effector nuclease
(TALEN) assembly kit [13] and to enable efficient expres-
sion in mammalian cells, two additional expression plas-
mids – pTAL7A and pTAL7B – were generated. The
main features of these vectors include (i) a CAG promoter
with a chimeric intron and a Kozak sequence for efficient
TALEN expression in mammalian cells, (ii) Esp3I (BsmBI)
restriction sites for GoldenGate cloning, (iii) a lacZ frag-
ment for blue/white-screening in E.coli, (iv) an improved,
truncated TALE backbone architecture similar to the one
established by Miller et al. [6], as well as (v) individual se-
lection cassettes for enrichment of double-transfected
cells. Hence, pTAL7A contains a constitutively expressed
Puromycin resistance gene linked to green fluorescent
protein, whereas pTAL7B contains a Blasticidin resistance
cassette (Table 1, Figure 1A, Additional file 1: Figure S1).
This is to enrich for double-transfected cells in hard-to-
manipulate cell lines such as human pluripotent stem
cells (hPSCs) – embryonic stem cells (hESCs) and in-
duced pluripotent stem cells (hiPSCs) – employing tran-
sient administration of the two antibiotics following
TALEN transfection.
To demonstrate the functionality of the combined sys-
tem, we designed 3 pairs of TALENs targeting exon 2 of
the HPRT1 gene (Additional file 1: Table S1). HPRT1 is lo-
cated on the X chromosome and mutations in this gene
cause Lesch-Nyhan-Syndrome (LNS), a disease with strong
neurological symptoms [14,15]. Cells without functional
HPRT1 can be selected via 6-thioguanine, a guanine
analogue that is metabolized by HPRT1 and introduced
into the DNA, resulting in mutagenesis and cell death
(Figure 1B). Robust expression of cloned TALEN and
Table 1 Comparison of pTAL4 and pTAL7 vector systems
pTAL4 pTAL7
Site for GoldenGate TALEN Assembly Esp3I Esp3I
Bacterial Resistance Ampicillin Kanamycin
Screening for successful cloning LacZ LacZ
TALEN architecture Full length Voytas et al. [13] Truncated C- & N-termini similar to Miller et al. [6]
FokI nuclease Wild-type Wild-type
Expression system Yeast Mammalian cells (CAG promoter + chimeric intron + Kozak sequence)
Enrichment of transfected cells - GFP & Puromycin (pTAL7A) Blasticidin (pTAL7B)
In-vitro transcription - T7 promoter
Codon usage Not optimized for mammalian cells Optimized for mammalian cells
Tag - Flag tag
Figure 1 Pretesting of TALENs and mutational spectra in 293 T cells and hPSCs. A: Illustration of GoldenGate TALEN assembly by
Cermak et al. [13] and cloning into new expression vectors pTAL7A and pTALB. Note that the number of RVDs is not limited to 18 but flexible.
B: Schematic of negative selection of HPRT1 knock-out cells by 6-thioguanine (6-TG). 6-TG results in death of cells with functional HPRT1. C: Cel-1
assay following transfection with three TALEN pairs (#1 to #3). Arrows indicate expected fragment sizes following Cel-1 digest of reannealed
HPRT1 genomic PCRs (gPCR) as a result of error-prone NHEJ. Control plasmid (GFP) transfected cells served as negative control. Percentage of
non-homologous end-joining (NHEJ) is indicated below each lane. D: Surviving 293 T cells following TALEN transfection and 6-TG selection of
HPRT1 mutants. E: TALEN-induced mutation spectrum. Underlined wild-type sequence indicates binding region of TALEN pair #2. Mutant se-
quences shown are individual gPCR clones from bulk 6-TG selected cultures following transfection of TALEN pair #2. F: Pretesting of TALEN pairs
#1 to #3 in HuES6 hESCs. Note that mutation efficiencies are somewhat decreased compared to 293 T cells in part B. G: Bulk hESC cultures follow-
ing TALEN #2 transfection and 6-TG selection. H: TALEN-induced mutation spectrum in hESCs. All transfected cells were enriched by transient
puromycin/blasticidin administration.
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qRT-PCR (Additional file 1: Figure S2A,B). TALEN con-
structs were once more transfected into 293 T cells, transi-
ently incubated at 37°C and 30°C to also investigate effects
of low-temperature incubation on non-homologous end
joining (NHEJ)-based mutation frequencies [6]. HPRT1
PCRs on isolated genomic DNA were denatured, rean-
nealed, and subjected to Cel-1 digestion and gel electro-
phoresis to reveal the generation of small genetic lesions in
these bulk cultures. Specificity of DNA-binding of TALENs
is mediated by two amino acids in each of the individual
repeat domains, the so-called repeat variable di-residue
(RVD). Several RVDs have been found to bind with dif-
ferent affinities to their target nucleotide [5]. Using
TALENs employing only the “NK” RVD for targeting
guanine did not produce detectable Cel-1 digestion frag-
ments (Figure 1B, top panel). However, replacing “NK” by
“NN” RVDs at strategic positions, as previously suggested
[4,5], revealed that all three tested TALENs were func-
tional as their delivery into 293 T cells apparently caused
robust introduction of small lesions in HPRT1 (Figure 1C,
bottom panel, Additional file 1: Table S1). A transient
cold-shock at 30°C did not have a significant effect on in-
duction of double-strand breaks (DSBs) (Figure 1C). Func-
tional selection of HPRT1 mutant cells using the 6-TG
confirmed these results in that all three TALENs produced
6-TG resistant cells, at varying efficiencies (Figure 1D). Se-
quencing of PCR clones from these 6-TG selected cultures
showed that TALEN delivery mostly resulted in small de-
letions, implying that resulting frame shifts were the
causes of disrupting HPRT1 function (Figure 1E).
We then asked if it was possible to pre-test TALEN
pairs directly in hESCs. Indeed, the results were similar in
that TALEN pair #2 appeared to cut its target site most ef-
ficiently, albeit the obtained Cel-1 signals were somewhat
weaker than in 293 T cells (Figure 1F). 6-TG selection
functionally confirmed the disruption of the HPRT1 gene
in hESCs as numerous resistant colonies appeared with
two out of three TALEN pairs tested (Figure 1G). Analysis
of the mutational spectrum in hESCs by sequencing of
PCR clones revealed that mostly deletions as well as few
insertions had been introduced by TALEN delivery, like in
293 T cells (Figure 1H).
To ask if the pTAL7 vectors indeed present an improve-
ment over the existing platform using mammalian cells,
the same TALEN pair #2 was employed both in the context
of the original pTAL4 and the new pTAL7 expression vec-
tors. Both in 293 T cells and hESCs, we failed to detect any
evidence for error-prone NHEJ with the pTAL4 vectors
(Figure 2A). Selection with 6-TG functionally confirmed
these results (Figure 2B, Additional file 1: Figure S2C,D).
Furthermore, we asked if the performance of our expres-
sion vectors could be further improved by replacing wild-
type FokI nuclease domain by the sharkey variant whichwas previously reported to increase DSB formation [20].
However, with the present system, sharkey FokI did not
yield higher numbers of 6-TG resistant cells (Additional
file 1: Figure S2C,D). Despite this fact, these data suggest
that the pTAL7 vectors enable robust targeted mutagenesis
compared to the original system.
Next, we sought to quantify mutation frequencies in
hESCs by determining the ratio of surviving 6-TG resist-
ant hESC colony numbers by the total number of colonies
emerging in the absence of 6-TG. Using pre-selection of
double-transfected hESCs by puromycin and blasticidin,
functional HPRT1 mutations were introduced in approxi-
mately 15% of cells. Mutation rates without pre-selection
were low (0.5%), reflecting the usefulness of these resist-
ance cassettes in the pTAL7 vectors (Figure 2C).
In order to test the applicability of our system to loci
other than HPRT1, we employed TALENs targeting the
OCT4 [1] as well as the FOXC1 locus. Transfection into
hESCs and subsequent analysis showed robust induction
of error-prone NHEJ in both these genes (Figure 2D).
Moreover, to demonstrate that clonal knock-out hESC
lines could be isolated without the option of functional
negative selection (as with 6-TG), randomly picked col-
onies emerging after HPRT1 TALEN transfection were ex-
panded and screened for genomic lesions. Mutant clone
screening was in this case performed based on potential
disruption of a restriction enzyme recognition site within
the TALEN targeting region. Of the 19 clones analyzed, 5
showed an undigested PCR band (Figure 2E) suggesting at
least heterozygous mutations. We further analyzed these
clones using 6-TG as well as sequencing of the HPRT1
locus. One clone showed small deletions in both alleles
and was subsequently functionally confirmed to be 6-TG
resistant (#14 in Figure 2E). These data demonstrate the
universal applicability of the combined GoldenGate/pTAL7
TALEN system for generating knock-out hESC lines with-
out the need for additional gene targeting vectors or nega-
tive selection procedures.
We next sought to demonstrate the usefulness of the
system in the context of human disease modeling. To
this end, 5 additional 6-TG resistant HuES6 hESC clones
were expanded and sequenced. All 5 clones had muta-
tions in both HPRT1 alleles, with 3 clones being homo-
zygous and 2 heterozygous (Figure 3A), suggesting a loss
of X chromosome inactivation in all 5 clones [18]. Con-
versely, performing the same experiment with low-passage
female hiPSCs that presumably have not undergone loss
of X inactivation [18] produced 6-TG resistant clones with
both homo- and heterozygous HPRT lesions (data not
shown). To rule out that loss of one X-chromosome was
the reason for detecting only one specific mutation in
three of the hESC mutant clones, qPCR using an X-linked
marker verified that all clones had retained both X-
chromosomes (Figure 3B). Furthermore, no traces of the
Figure 2 Improved mutagenesis and universal applicability of the pTAL7 vector system. A: Cel-1 assay following transfection of 293 T and
hESCs with HPRT1 talen pair #2 in different expression vector backbones. B: Functional confirmation of results in (A) by 6-TG selection. C: Quantifi-
cation of functional mutations in HPRT1 following 6-TG selection, based on scoring of colony numbers. For the control without antibiotics and
the pTAL4 vectors, no puromycin/blasticidin selection was performed. Note the strong increase in mutation rates upon pre-selection for double-
transfected cells using transient administration of antibiotics. Error bars: SEM (n = 4). D: Applicability of the pTAL7 system to alternative genomic
loci as shown by Cel-1 assay (left panel) or restriction digestion (right panel: NHEJ is indicated by enrichment of undigested fragments). hESCs
were transfected with either a GFP control vector or the respective TALEN vectors, followed by subsequent gPCR amplification of TALEN target
regions. E: Restriction digestion and characterization of 19 clones expanded after TALEN transfection without 6-TG selection. Except in panel C,
pTAL7-transfected cells were routinely enriched by transient puromycin/blasticidin administration.
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these clones (Figure 3C), suggesting that transient anti-
biotic selection did not favor integration of the pTAL7
vectors. In order to investigate putative off-target cleavage
of HPRT1 TALENs, five putative off-target loci were
screened for unwanted mutation events in the five clonal
HPRT1 knock-out cell lines. Off-target effects were de-
tected in none of these sites (Figure 3D).
In order to investigate whether neurons derived from
HPRT1 mutant cell lines recapitulated disease phenotypes
in vitro, as recently shown in case of patient-specific
Lesch-Nyhan Syndrome (LNS) hiPSCs [18], wild-type and
mutant cell lines were differentiated into central nervoussystem (CNS) neurons. Compared to isogenic parental
control cells, all 5 knock-out clones appeared to show im-
paired neuronal differentiation, based on immunofluores-
cence analysis (Figure 4A). Quantitative analysis of these
differentiated cultures revealed a reduced overall number
of neurons together with a strong decrease in average
neurite length (Figure 4B). To see if a phenotype could also
be assigned to neurons of the peripheral nervous system,
we also conducted differentiation into sensory-like neurons
[19]. Indeed, quantification of the average neurite length of
BRN3A-postive neurons growing out from plated embry-
oid bodies revealed a similar phenotype with significantly
shorter neurites in HPRT1-targeted cells (Figure 4C,D).
Figure 3 Functional characterization of HPRT1 knock-out cell lines. A: HPRT1 lesions identified in 5 clonal hESC mutant lines. 10 PCR clones
were sequenced per cell line. Wild-type sequences shown on top were not seen in any case suggesting that cell clones 1–3 are homozygous.
Inserted DNA sequence of clone 5 is given in Additional file 1. B: Quantification of X chromosome copy number in clonal HPRT1 mutant lines
using genomic qPCR for an X-linked locus, based on qPCR quantification. Note that all mutant clones cluster with the female parental control.
C: Diagnostic PCR for detecting possible random integration of vector sequences into the genome of TALEN-treated cell clones. Analysis was
performed at passage 5 after 6-TG selection. Original pTAL7 vectors served as positive control and isogenic parental cells served as negative
control. D: PCR and subsequent Cel-1 assay for detection of mutations at the 5 most probably putative TALEN off-target cleavage sites in clonal
HPRT1 knock-out cell lines. Genomic DNA from parental hESCs served as control. Note that the additional band in off-target site 1 probably results
from a single nucleotide polymorphism and that there are no differences between clonal HPRT1 knock-out cell lines and the parental control.
TALEN off-target binding sites are depicted in the right panel with mismatches indicated by asterisks.
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like neurons could also be observed with independent cell
lines, we generated HPRT1 knock-out clones from induced
pluripotent stem cells, in the same manner as described
above for hESCs. Parental hiPSCs and five independent
mutant clones were once more differentiated into BRN3A-
positive neurons, to quantify resulting average neurite
lengths. Again, loss of functional HPRT1 resulted in signifi-
cantly shorter neurites (Figure 4E) in the mutant clones as
compared to parental controls. Taken together, these data
demonstrate the applicability of the combined TALEN sys-
tem to genetic disease modeling based on isogenic pairs of
mutant and wild-type hPSC lines.
Discussion
TALENs have become a valuable tool for genome editing
in a variety of cell types, including hPSCs [1,7,21]. Overthe past few years, various methods to assemble TALENs
have been developed, ranging from gene synthesis to
manual cloning kits and automated high-throughput sys-
tems [7-11,13]. The GoldenGate TALEN assembly kit by
Cermak et al. is publicly available, straightforward to es-
tablish in the laboratory, reliable, as well as time and cost-
efficient [13]. However, the final expression vectors of this
kit were not optimized for application in mammalian cells.
Furthermore, modifications of the TALEN domain archi-
tecture shown to improve DSB induction [6] were not
included in the expression vectors. The pTAL7 vectors de-
scribed here are fully compatible with the GoldenGate
TALEN kit [13], yet overcome these drawbacks. They en-
abled robust induction of DSBs in human cell lines, in-
cluding hPSCs, resulting in functional gene knock-out
without the need of conventional targeting vectors. The
selection cassettes implemented in the plasmids enable
Figure 4 Neural differentiation of HPRT1 knock-out cell lines. A: Neuronal phenotypes in isogenic HPRT1 mutant hESC lines. Beta-III-tubulin-
stained CNS neurons derived from 5 independent HPRT1 mutant lines and isogenic wild-type control. Note the higher numbers with more
pronounced neurites in wild-type compared to mutant cells. B: High-content imaging-based quantification of neuron formation frequencies
and neurite lengths of cultures shown in A. P-values are based on unpaired t-tests between individual clones and wild-type control samples.
*: p≤ 0.05; **: p≤ 0.01; ***p≤ 0.001. C: Neurons growing out in a radial manner from plated embryoid bodies induced to differentiate into
BRN3A-positive PNS neurons. Images show representative outgrowths stained for beta-III-tubulin under 50x magnification. Sphere radius values
served as an approximation for quantifying relative neurite lengths. D: Quantification of sizes of replicate plated spheres shown in C (n≥ 7).
E: Quantification of sizes of replicate plated spheres from HPRT1 knock-out hiPSCs differentiated into sensory-like neurons as in C (n≥ 8). P-values
are based on unpaired t-tests between individual clones and wild-type controls. **: p≤ 0.01; ***p≤ 0.001.
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be key for obtaining high mutation frequencies in our
hands. Pre-selection for double transfectants will particu-
larly be necessary in cases where negative functional selec-
tion as in case with HPRT1/6-TG is not an option. Indeed,
we demonstrate that the pTAL7 vectors permitted the iso-
lation of hPSC knock-out lines without applying 6-TG
selection, based solely on random picking of clones. Incomparison with enrichment methods relying on fluores-
cent marker proteins [7], the pTAL7 system offers both
antibiotic and fluorescent selection of transfected cells,
making it highly versatile and independent of the availabi-
lity of cell sorting instrumentation. Furthermore, conven-
tional lipofection as a delivery method yielded sufficient
numbers of clones with small amounts of starting cells, in
contrast to methods based on electroporation [1,7].
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cell-derived CNS neurons recapitulated aspects of im-
paired neurogenesis in LNS patients and were in line
with observations made with patient-specific hiPSCs, al-
beit showing an overall higher number of differentiated
neurons in our hands [18]. These differences may be
explained with differences among individual hPSC lines,
supporting the necessity of isogenic disease models. Future
experiments could address the effects of HPRT1 knock-out
on neuronal differentiation side-by-side in engineered
hESCs and patent-specific hiPSCs. In addition, impaired
neurite outgrowth was also observed in BRN3A-positive
neurons [19], extending these findings to the PNS system.
Notably, these phenotypes were observed in independent
clones of independent cell lines (hESCs & hiPSCs) and
in comparison to isogenic parental controls, which de-
monstrates a causative role of mutant HPRT1 irrespective
of the genetic background. It would be worthwhile further
investigating this effect on sensory-like neurons to study
functional links to LNS phenotypes. Taken together, the
observed cellular phenotypes confirm that TALEN-
mediated mutagenesis in wild-type hPSCs is a valid alter-
native for disease modeling without the need for patient
material and lengthy reprogramming as well as hiPSC
characterization procedures [22]. Introduction of more
subtle lesions or gene correction approaches would be
enabled by employing conventional gene targeting vec-
tors in addition to the TALEN constructs [23]. Further-
more, the system is not limited to using hPSCs, as we
have also successfully used it in HEK-293 T, HeLa, and
mouse ES cells (Figure 1C-E, and data not shown).
The field of targeted genetic engineering is rapidly
evolving. For example, RNA-protein-mediated DSB in-
duction by the CRISPR-Cas9 system has recently been
shown to efficiently enhance gene targeting in a variety
of organisms and cell types, including hPSCs, similar to
TALENs [22,24-30]. However, comprehensive studies ad-
dressing target specificity of this new platform are yet to
be carried out, with regards to the shorter binding se-
quence of CRISPRs compared to TALENs as well as re-
garding the tolerance of single-base mismatches in the
recognition sequence. Likely, future investigation will be
based on several well-working genetic engineering sys-
tems that may be selectively employed depending on
their respective strengths and weaknesses.Conclusion
The improved TALEN system evaluated in this work
presents an affordable and easy-to-adopt methodology
to facilitate gene targeting in human pluripotent stem
cells and other mammalian cell types. It will thus be
helpful for developmental studies as well as disease
modeling approaches.Additional file
Additional file 1: Supporting Information, including detailed
description of methods, TALEN sequences as well as additional
figures.
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